@article{4efcc21776be40509f8bf43509f62ed0,
title = "Perception of severity of adverse events in oral immunotherapy – Authors' reply",
author = "{PACE study group} and Chu, {Derek K.} and Wood, {Robert A.} and Shannon French and Alessandro Fiocchi and Susan Waserman and Sch{\"u}nemann, {Holger J.}",
note = "Funding Information: DKC is a member of the GRADE working group. DKC and SW are investigators in an ongoing peanut oral immunotherapy trial ( NCT01601522 ) funded by AllerGen NCE through the Government of Canada, who are blinded to the results of the study. RAW reports grants from the US National Institutes of Health, Astellas, Aimmune, DBV Technologie, Sanofi, and Regeneron, and personal fees from the American Academy of Allergy Asthma and Immunology and UpTo Date, outside the submitted work. SW reports grants from Aimmune, and personal fees from Pfizer, Mylan, and Sanofi, outside the submitted work. HJS is co-chair of the GRADE working group. All other authors declare no competing interests.",
year = "2020",
month = feb,
day = "8",
doi = "10.1016/S0140-6736(19)32567-X",
language = "English (US)",
volume = "395",
pages = "415--416",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "10222",
}